These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Lymphokine-activated killer lymphocytes: National Cancer Institute clinical trials. Clark J; Longo DL Immunol Ser; 1989; 48():37-58. PubMed ID: 2488325 [No Abstract] [Full Text] [Related]
5. Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system. Blacklock JB; Grimm EA Immunol Ser; 1989; 48():93-9. PubMed ID: 2488328 [No Abstract] [Full Text] [Related]
6. [Interleukin-2 and adoptive immunotherapy: their biological aspects and clinical application in oncology]. Barón Saura JM; Pizarro Redondo A; Berrocal Jaime A; González Barón M Rev Clin Esp; 1991 May; 188(9):468-72. PubMed ID: 1896596 [TBL] [Abstract][Full Text] [Related]
9. Clinical use of interleukin-2 in treating cancer. Patterson DL; Wiemann MC Indiana Med; 1991 Aug; 84(8):534-7. PubMed ID: 1918915 [No Abstract] [Full Text] [Related]
10. [Our experience with lymphocytes activated against cancer: CTL cells]. Marcellino LR; Vinciguerra M; Marcellino MV; Sessa E G Chir; 1997 Oct; 18(10):605-7. PubMed ID: 9479972 [TBL] [Abstract][Full Text] [Related]
11. Adoptive cellular immunotherapy for cancer: interleukin-2 activated lymphocytes. Wolf JA; Grimm EA Curr Opin Oncol; 1989 Dec; 1(2):249-57. PubMed ID: 2489968 [No Abstract] [Full Text] [Related]
12. The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer. Yannelli JR J Immunol Methods; 1991 May; 139(1):1-16. PubMed ID: 2040807 [No Abstract] [Full Text] [Related]